Discontinued — last reported Q1 '26
Other pharmaceutical — Sales
Merck & Co. Other pharmaceutical — Sales decreased by 40.4% to $775.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 46.8%, from $1.46B to $775.00M. Over 4 years (FY 2021 to FY 2025), Other pharmaceutical — Sales shows an upward trend with a 6.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests successful lifecycle management or growth in niche therapeutic areas, while a decrease may indicate product maturity, patent expirations, or strategic divestitures.
Detailed definition
This metric represents the total revenue generated from the company's secondary or non-core pharmaceutical product lines...
Peer comparison
Peers typically report this as 'Other' or 'Diversified' segment revenue, often representing a mix of mature products, consumer health, or specialized niche therapies.
mrk_segment_other_pharmaceutical_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.09B | $1.14B | $0.00 | $1.04B | $958.00M | $1.13B | $1.37B | $1.17B | $1.11B | $1.10B | $1.19B | $1.15B | $1.15B | $1.28B | $1.44B | $1.46B | $1.17B | $1.91B | $1.30B | $775.00M |
| QoQ Change | — | +4.6% | -100.0% | — | -7.9% | +17.8% | +21.6% | -14.8% | -5.5% | -0.6% | +8.5% | -3.4% | -0.3% | +11.7% | +12.0% | +1.5% | -19.8% | +63.1% | -31.8% | -40.4% |
| YoY Change | — | — | — | — | -12.3% | -1.1% | — | +12.5% | +15.4% | -2.7% | -13.2% | -1.5% | +3.9% | +16.7% | +20.6% | +26.6% | +1.8% | +48.7% | -9.5% | -46.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s other pharmaceutical — sales?
- Merck & Co. (MRK) reported other pharmaceutical — sales of $775.00M in Q1 2026.
- How has Merck & Co.'s other pharmaceutical — sales changed year-over-year?
- Merck & Co.'s other pharmaceutical — sales decreased by 46.8% year-over-year, from $1.46B to $775.00M.
- What is the long-term trend for Merck & Co.'s other pharmaceutical — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s other pharmaceutical — sales has grown at a 6.0% compound annual growth rate (CAGR), from $4.63B to $5.84B.
- What does other pharmaceutical — sales mean?
- The total revenue generated from the company's secondary or non-core pharmaceutical product lines.